Facilitating optimal use of contrast, the Medrad Centargo CT Injection System reportedly combines user-friendly features with workflow efficiency for high-volume CT departments.
The Food and Drug Administration (FDA) has granted 510(k) clearance to the Medrad Centargo CT Injection System, which enables contrast administration for multiple patients undergoing computed tomography (CT) exams.
Featuring a pre-assembled Day Set and a snap-in patient line that auto-primes upon insertion, the Medrad Centargo CT Injection System allows contrast set-up for multiple patients to be completed in less than two minutes, according to Bayer, the manufacturer of the Medrad Centargo CT Injection System.
For demanding CT protocols, Bayer said the system also has a Dual Flow feature that allows simultaneous administration of contrast and saline, which is facilitated by the Medrad Centargo CT Injection System’s piston-based technology.
The combination of automated documentation software and the system’s integrated barcode reader enables simplified access to contrast and injection details to help streamline reporting.
“We know radiologists today are facing a continuously increasing workload, and the automation, integration and mobility of the Medrad® Centargo CT Injection System helps radiology staff do more with less, allowing them more time to focus on their patients,” noted Sven Schmidt, the head of Region Americas Radiology at Bayer.
Seven Takeaways from New CT and MRI Guidelines for Ovarian Cancer Staging
January 20th 2025In an update of previous guidelines from the European Society of Urogenital Radiology published in 2010, a 21-expert panel offered consensus recommendations on the utility of CT, MRI and PET-CT in the staging and follow-up imaging for patients with ovarian cancer.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
New CT and MRI Research Shows Link Between LR-M Lesions and Rapid Progression of Early-Stage HCC
January 2nd 2025Seventy percent of LR-M hepatocellular carcinoma (HCC) cases were associated with rapid growth in comparison to 12.5 percent of LR-4 HCCs and 28.5 percent of LR-4 HCCs, according to a new study.